Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-521 in healthy volunteers and chronic hepatitis B patients
NCT02797522Phase 1Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ARC-521 in Chronic Hepatitis B (CHB) (11 arms), sponsored by Arrowhead Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events at 29 days, Area Under the Plasma-Concentration-Time Curve From Time 0-24 Hours at 48 hours and 8 more. Started Jun 2016; status: terminated.
02
Drugs
ARC-521
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02797522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797522.